Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Vilon (VIL) is a anti-aging peptide, at the approved (russia) stage in the published literature. Vilon (Lys-Glu or KE) is one of the most studied Khavinson bioregulatory peptides, developed at the Saint Petersburg Institute of Bioregulation and Gerontology. Vilon is classified as an immunomodulatory bioregulator — a dipeptide consisting of lysine and glutamic acid that targets immune system tissues. Research suggests these short peptides can penetrate the cell nucleus and interact with specific DNA sequences, modulating gene expression related to cell differentiation, proliferation, and apoptosis. Vilon has been shown to restore thymic function in aging organisms, promote T-cell differentiation, and enhance immune surveillance.
Vilon (Lys-Glu or KE) is one of the most studied Khavinson bioregulatory peptides, developed at the Saint Petersburg Institute of Bioregulation and Gerontology. Vilon is classified as an immunomodulatory bioregulator — a dipeptide consisting of lysine and glutamic acid that targets immune system tissues. Research suggests these short peptides can penetrate the cell nucleus and interact with specific DNA sequences, modulating gene expression related to cell differentiation, proliferation, and apoptosis. Vilon has been shown to restore thymic function in aging organisms, promote T-cell differentiation, and enhance immune surveillance.
| Research Status | Approved (Russia) |
|---|---|
| Half-Life | Short (dipeptide, rapid absorption) |
| Administration | Oral, Sublingual |
| Doses Reported in Published Studies | 10-20 mcg oral |
| Molecular Weight | 275.3 Da |
| Molecular Formula | C10H19N3O5 |
Vilon acts as a bioregulator by interacting with DNA and modulating gene expression in immunocompetent cells. It promotes differentiation of immune progenitor cells and enhances thymic function. As a short peptide, it can penetrate cell membranes and interact directly with chromatin.
Vilon (Lys-Glu or KE) is one of the most studied Khavinson bioregulatory peptides, developed at the Saint Petersburg Institute of Bioregulation and Gerontology. Vilon is classified as an immunomodulatory bioregulator — a dipeptide consisting of lysine and glutamic acid that targets immune system tissues. Research…
Vilon acts as a bioregulator by interacting with DNA and modulating gene expression in immunocompetent cells. It promotes differentiation of immune progenitor cells and enhances thymic function. As a short peptide, it can penetrate cell membranes and interact directly with chromatin.
Vilon is at the following stage in the published literature: Approved (Russia). All information is for research and educational purposes only.
Reported half-life: Short (dipeptide, rapid absorption).
Reported administration route in the literature: Oral, Sublingual. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.